^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19/BAFF-R dual CAR T

    i
    Other names: CD19/BAFF-R dual CAR T
    Associations

    News

    Trials
    Company:
    City of Hope
    Drug class:
    CD19-targeted CAR-T immunotherapy, BAFF-R-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over2years
    CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. (PubMed, Leukemia)
    Further, CD19/BAFF-R dual CAR T cells showed prolonged in vivo persistence, raising the possibility that these cells may have the potential to promote durable remissions. Together, our data support clinical translation of BAFF-R/CD19 dual CAR T cells to treat ALL.
    Journal • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19/BAFF-R dual CAR T
    3years
    CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia (ASH 2021)
    Our study demonstrated the reliability of bispecific CD19/BAFF-R dual CAR T cell therapy in inducing remission in ALL consisting of CD19-/- and BAFF-R-/- tumors. We hypothesize that simultaneous immunotherapy targeting of heterogeneous leukemic cell populations may diminish the likelihood of antigen escape and may have a significant impact on leukemia treatment by improving the therapeutic benefits of CAR T cell therapy.
    CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule)
    |
    CD19/BAFF-R dual CAR T